PharmaCyte CEO resigns; interim CEO appointed; Board forms Business Review Committee to evaluate strategic options

PharmaCyte Biotech, Inc.

CEO Kenneth Waggoner resigned effective Oct 6; separation agreement provides $216,667 lump sum and $433,333 consulting payments over 12 months.
Board appointed Joshua Silverman as interim CEO and Chairman; Silverman is a director since Aug 2022 and co-founder of Parkfield Funding.
Board's Business Review Committee to evaluate opportunities including FDA clinical hold on Cell-in-a-Box IND and relationship with SG Austria.
Company continuing share repurchase program of up to $10 million; spending on programs curtailed pending review.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Joshua N. Silverman

interim Chairman of the Board, interim Chief Executive Officer and interim President

PMCB · PharmaCyte Biotech, Inc.

Effective: 2022-10-06
Filed: October 7, 2022, 7:59 PM ET

Effective October 6, 2022, the Board appointed Joshua N. Silverman, a director on the Board since August 2022, as interim Chairman of the Board, interim Chief Executive Officer and interim President of the Company.

Departed

Kenneth L. Waggoner

Chief Executive Officer, President and General Counsel

PMCB · PharmaCyte Biotech, Inc.

Effective: 2022-10-06
Successor: Joshua N. Silverman
Filed: October 7, 2022, 7:59 PM ET

Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech , Inc. ( the “Company”) resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the “Company Group”) and as a director on the Board of Directors of the Company (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua N. Silverman was appointed as interim Chairman of the Board, interim Chief Executive Officer and interim President at PharmaCyte Biotech, Inc..

Action: appointed
Role: interim Chairman of the Board, interim Chief Executive Officer and interim President

Exact text from the filing

Effective October 6, 2022, the Board appointed Joshua N. Silverman, a director on the Board since August 2022, as interim Chairman of the Board, interim Chief Executive Officer and interim President of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth L. Waggoner resigned as Chief Executive Officer, President and General Counsel at PharmaCyte Biotech, Inc..

Action: resigned
Role: Chief Executive Officer, President and General Counsel

Exact text from the filing

Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech , Inc. ( the “Company”) resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the “Company Group”) and as a director on the Board of Directors of the Company (the “Board”).

View on SEC.gov

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-006803

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.